Literature DB >> 28344790

Prognostic factors of hepatocellular carcinoma survival after radiofrequency ablation: A US population-based study.

Mohamed Abd El-Fattah1, Mohamed Aboelmagd2, Mohammed Elhamouly2.   

Abstract

OBJECTIVE: To determine the survival outcome and prognostic factors of hepatocellular carcinoma (HCC) survival in patients who underwent radiofrequency ablation (RFA).
METHODS: The Surveillance, Epidemiology and End Results (SEER) database was queried: There were 2588 HCC patients from 2004 to 2012 who underwent RFA. The Kaplan-Meier curves and the multivariate Cox regression analysis were used to assess the prognostic factors.
RESULTS: With a median follow-up of 20 months, the 1-, 3- and 5-year overall survival (OS) rates were: 83%, 51% and 33%. Patients with a tumor size ≤5 cm in diameter had a better 5-year OS, as compared to patients with a tumor size >5 cm. The 5-year OS was significantly higher among patients with a normal level of alpha-fetoprotein (AFP), compared with those having elevated AFP. In an adjusted multivariate Cox regression analysis, those with ≥60 years of age (HR: 1.19; 95% CI 1.05-1.36), non-Asian race (HR: 1.53; 95% CI 1.30-1.81), tumor size >5 cm (HR: 1.43; 95% CI 1.24-1.65), elevated AFP (HR: 1.42; 95% CI 1.22-1.64), American Joint Committee on Cancer (AJCC) stages II-III (HR: 1.30; 95% CI 1.14-1.48) and the year of diagnosis from 2004-2007 (HR: 1.22; 95% CI 1.07-1.40) were significantly associated with a poor prognosis.
CONCLUSIONS: Age, race, tumor size, AFP level, AJCC stage and year of diagnosis were prognostic factors for OS in HCC patients who underwent RFA.

Entities:  

Keywords:  Alpha fetoprotein; SEER database; database analysis; hepatocellular carcinoma; liver cancer; prognostic factors; radiofrequency ablation; survival

Year:  2016        PMID: 28344790      PMCID: PMC5349365          DOI: 10.1177/2050640616659024

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN: 2050-6406            Impact factor:   4.623


  47 in total

Review 1.  Local ablation therapy for hepatocellular carcinoma: current status and future perspectives.

Authors:  Masatoshi Kudo
Journal:  J Gastroenterol       Date:  2004       Impact factor: 7.527

Review 2.  Current strategy for staging and treatment: the BCLC update and future prospects.

Authors:  Alejandro Forner; María E Reig; Carlos Rodriguez de Lope; Jordi Bruix
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

3.  Predictors of Survival in Hepatocellular Carcinoma Patients.

Authors:  Hale Gokcan; Nurten Savaş; Derya Oztuna; Gokhan Moray; Fatih Boyvat; Mehmet Haberal
Journal:  Ann Transplant       Date:  2015-10-06       Impact factor: 1.530

Review 4.  Histological grading and staging of chronic hepatitis.

Authors:  K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween
Journal:  J Hepatol       Date:  1995-06       Impact factor: 25.083

5.  Alpha-fetoprotein and tumour size are associated with microvascular invasion in explanted livers of patients undergoing transplantation with hepatocellular carcinoma.

Authors:  Patrick P McHugh; Jeffrey Gilbert; Santiago Vera; Alvaro Koch; Dinesh Ranjan; Roberto Gedaly
Journal:  HPB (Oxford)       Date:  2010-02       Impact factor: 3.647

Review 6.  Chronic hepatitis B and hepatocellular carcinoma.

Authors:  Amy C McClune; Myron J Tong
Journal:  Clin Liver Dis       Date:  2010-08       Impact factor: 6.126

7.  Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ≤3 cm. Results of a multicenter Italian survey.

Authors:  Maurizio Pompili; Antonio Saviano; Nicoletta de Matthaeis; Alessandro Cucchetti; Francesco Ardito; Bruno Federico; Franco Brunello; Antonio D Pinna; Antonio Giorgio; Stefano M Giulini; Ilario De Sio; Guido Torzilli; Fabio Fornari; Lorenzo Capussotti; Alfredo Guglielmi; Fabio Piscaglia; Luca Aldrighetti; Eugenio Caturelli; Fulvio Calise; Gennaro Nuzzo; Gian Ludovico Rapaccini; Felice Giuliante
Journal:  J Hepatol       Date:  2013-03-22       Impact factor: 25.083

8.  Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.

Authors:  Willscott E Naugler; Toshiharu Sakurai; Sunhwa Kim; Shin Maeda; Kyounghyun Kim; Ahmed M Elsharkawy; Michael Karin
Journal:  Science       Date:  2007-07-06       Impact factor: 47.728

9.  Noninvasive fibrosis indices predict intrahepatic distant recurrence of hepatitis B-related hepatocellular carcinoma following radiofrequency ablation.

Authors:  Ji Yeon Seo; Won Kim; Jee Hye Kwon; Eun Hyo Jin; Su Jong Yu; Hwi Young Kim; Yong Jin Jung; Donghee Kim; Yoon Jun Kim; Jung-Hwan Yoon; Hyo-Suk Lee
Journal:  Liver Int       Date:  2013-03-05       Impact factor: 5.828

10.  Percutaneous thermal ablation of medium and large hepatocellular carcinoma: long-term outcome and prognostic factors.

Authors:  Xiao-Yu Yin; Xiao-Yan Xie; Ming-De Lu; Hui-Xiong Xu; Zuo-Feng Xu; Ming Kuang; Guang-Jian Liu; Jin-Yu Liang; Wan Yee Lau
Journal:  Cancer       Date:  2009-05-01       Impact factor: 6.860

View more
  13 in total

1.  Hepatocellular carcinoma biology predicts survival outcome after liver transplantation in the USA.

Authors:  Mohamed Abd El-Fattah
Journal:  Indian J Gastroenterol       Date:  2017-02-14

2.  Expansion of Liver Transplantation Criteria for Hepatocellular Carcinoma from Milan to UCSF in Australia and New Zealand and Justification for Metroticket 2.0.

Authors:  Savio G Barreto; Simone I Strasser; Geoffrey W McCaughan; Michael A Fink; Robert Jones; John McCall; Stephen Munn; Graeme A Macdonald; Peter Hodgkinson; Gary P Jeffrey; Bryon Jaques; Michael Crawford; Mark E Brooke-Smith; John W Chen
Journal:  Cancers (Basel)       Date:  2022-06-03       Impact factor: 6.575

3.  Novel tumor suppressor SPRYD4 inhibits tumor progression in hepatocellular carcinoma by inducing apoptotic cell death.

Authors:  Kashif Rafiq Zahid; Shiming Han; Fuling Zhou; Umar Raza
Journal:  Cell Oncol (Dordr)       Date:  2018-09-20       Impact factor: 7.051

4.  Comparison of repeated surgical resection and radiofrequency ablation for small recurrent hepatocellular carcinoma after primary resection.

Authors:  Wei-Chi Sun; I-Shu Chen; Huei-Lung Liang; Cheng-Chung Tsai; Yu-Chia Chen; Being-Whey Wang; Huey-Shyan Lin; Hoi-Hung Chan; Ping-I Hsu; Wei-Lun Tsai; Jin-Shiung Cheng
Journal:  Oncotarget       Date:  2017-10-07

5.  Natural disease progression and novel survival prediction model for hepatocellular carcinoma with spinal metastases: a 10-year single-center study.

Authors:  Phichayut Phinyo; Chonmavadh Boonyanaruthee; Permsak Paholpak; Dumneoensun Pruksakorn; Areerak Phanphaisarn; Apiruk Sangsin
Journal:  World J Surg Oncol       Date:  2020-06-20       Impact factor: 2.754

6.  Radiofrequency ablation of hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-free survival.

Authors:  Andrea Casadei Gardini; Giorgia Marisi; Matteo Canale; Francesco Giuseppe Foschi; Gabriele Donati; Giorgio Ercolani; Martina Valgiusti; Alessandro Passardi; Giovanni Luca Frassineti; Emanuela Scarpi
Journal:  Onco Targets Ther       Date:  2018-10-05       Impact factor: 4.147

7.  A Nomogram Predicting Extrahepatic Metastases for Patients with Adjuvant Transarterial Chemoembolization after Hepatectomy.

Authors:  Shipeng Chen; Yuzhen Gao; Zheng Li; Jian'an Jia; Meng Fang; Mengmeng Wang; Huijuan Feng; Qinjunjie Chen; Wenqian Guan; Ziyi Wang; Chunfang Gao
Journal:  J Cancer       Date:  2018-10-20       Impact factor: 4.207

8.  Prognostic Biomarker Identification Through Integrating the Gene Signatures of Hepatocellular Carcinoma Properties.

Authors:  Jialin Cai; Bin Li; Yan Zhu; Xuqian Fang; Mingyu Zhu; Mingjie Wang; Shupeng Liu; Xiaoqing Jiang; Jianming Zheng; XinXin Zhang; Peizhan Chen
Journal:  EBioMedicine       Date:  2017-04-12       Impact factor: 8.143

9.  Liver-enriched Genes are Associated with the Prognosis of Patients with Hepatocellular Carcinoma.

Authors:  Binghua Li; Tiancheng Xu; Chaohui Liu; Gang Meng; Yuchen Sun; Liyuan Qian; Shaohe Wang; Jiwu Wei; Decai Yu; Yitao Ding
Journal:  Sci Rep       Date:  2018-07-25       Impact factor: 4.379

10.  ITGBL1 promotes cell migration and invasion through stimulating the TGF-β signalling pathway in hepatocellular carcinoma.

Authors:  Wei Huang; Demin Yu; Mingjie Wang; Yue Han; Junyu Lin; Dong Wei; Jialin Cai; Bin Li; Peizhan Chen; Xinxin Zhang
Journal:  Cell Prolif       Date:  2020-06-14       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.